Invitroimpact of pegvisomant on growth hormone-secreting pituitary adenoma cells

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study

(2015) Emmanuelle Kuhn et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion

(2015) Cuiqi Zhou et al.   JOURNAL OF CLINICAL INVESTIGATION

Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs

(2015) Philippe Chanson   NEUROENDOCRINOLOGY

Pegvisomant Treatment in Acromegaly

(2015) Sebastian J.C.M.M. Neggers et al.   NEUROENDOCRINOLOGY

STAT3 regulated ARF expression suppresses prostate cancer metastasis

(2015) Jan Pencik et al.   Nature Communications

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

(2014) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

(2014) John D. Carmichael et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Expert consensus document: A consensus on the medical treatment of acromegaly

(2014) Andrea Giustina et al.   Nature Reviews Endocrinology

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

Insulin and IGF-I Inhibit GH Synthesis and Release in Vitro and in Vivo by Separate Mechanisms

(2013) Manuel D. Gahete et al.   ENDOCRINOLOGY

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naïve patients with somatotroph adenomas

(2013) Sarah Larkin et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Growth hormone is a cellular senescence target in pituitary and nonpituitary cells

(2013) V. Chesnokova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Automated 22-kD Growth Hormone-Specific Assay without Interference from Pegvisomant

(2012) J. Manolopoulou et al.   CLINICAL CHEMISTRY

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Pegylated Growth Hormone Receptor Antagonist, Pegvisomant, Does Not Enter the Brain in Humans

(2010) Johannes D. Veldhuis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study

(2010) M. Marazuela et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly

(2009) Ignacio Bernabeu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

(2008) Camilo Jimenez et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY